Last reviewed · How we verify
IR103
IR103 is an immunotherapeutic agent designed to modulate immune response, likely through activation or enhancement of anti-tumor immunity.
At a glance
| Generic name | IR103 |
|---|---|
| Also known as | HIV-1 IMMUNOGEN + Amplivax, REMUNE + Amplivax |
| Sponsor | Immune Response BioPharma, Inc. |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
While specific mechanistic details for IR103 are limited in public literature, the drug appears to be developed by Immune Response BioPharma as an immunomodulatory therapeutic. Given the company's focus and the drug's phase 3 status, it likely works through enhancement of T-cell mediated immunity or checkpoint modulation to treat cancer or infectious diseases.
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |